research Delayed Granulomatous Eruption of the Nose Associated with Ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
Search
for
Sort by
Research
330-360 / 440 results
research Baricitinib Maintains Regrowth of Hair, Eyebrows, and Eyelashes Over 3 Years
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
research Treatment of Refractory Segmental Vitiligo and Alopecia Areata in a Child with Upadacitinib and NB-UVB: A Case Report
Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Alopecia Areata and Alopecia Areata Incognita
Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
research Experience with Oral Tofacitinib in Adolescents and Adults with Alopecia Areata
Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
research An Overview of Alopecia Areata: Etiopathogenesis, Diagnosis, and Management
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA
Alopecia areata leads to significantly higher healthcare costs due to more doctor visits and prescriptions.
research Predictive Modeling of Drug Response and Mechanism of Action in Alopecia Areata Clinical Trials
Researchers found three different ways drugs work to treat hair loss from alopecia areata and identified key factors for personalized treatment.
research The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research The Good and Bad News About New Drugs for Treating Alopecia Areata
JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.
research Treatment of Pediatric Alopecia Areata: A Systematic Review
Topical corticosteroids are the best initial treatment for children's alopecia areata.
research Association of Atopic Dermatitis With Autoimmune Diseases: A Bidirectional and Multivariable Two-Sample Mendelian Randomization Study
Atopic dermatitis increases the risk of some autoimmune diseases.
research Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
research Oral Tofacitinib: A Promising Treatment in Atopic Dermatitis, Alopecia Areata, and Vitiligo
Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Combination of Baricitinib and Conventional Immunomodulating Therapy for Alopecia Totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Are Janus Kinase (JAK) Inhibitors Beneficial in the Treatment of Androgenic Alopecia?
JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
research Gynostemma Pentaphyllum Hydrodistillate and Its Major Component Damulin B Promote Hair Growth via the Wnt/Beta-Catenin Pathway
Gynostemma pentaphyllum and its component damulin B could help hair grow by activating certain cell pathways.
research Topical Tofacitinib for Patients with Lichen Planopilaris and/or Frontal Fibrosing Alopecia
Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
research Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris
The best treatment for Frontal Fibrosing Alopecia and Lichen Planopilaris combines oral and topical medications to reduce symptoms and stop hair loss.
research Characterization of Novel TMEM173 Mutation with Additive IFIH1 Risk Allele
A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.
research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Time to Scalp Hair, Eyebrow, and Eyelash Improvement in Patients with Alopecia Areata Treated with Baricitinib in the Phase 2 Portion of the Phase 2/3 BRAVE-AA1 Study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report
Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.
research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: Evidence to Date
Baricitinib is a promising treatment for alopecia areata.
research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.